White House to open up negotiations with drug companies
To carry out the president's executive order aimed at reducing prescription drug prices, the White House said it will open up negotiations with drug companies sometime next month and eventually pursue formal rulemaking if no progress is made.
The White House expects at least some voluntary offers from companies, officials said, because a big component of this plan is to help companies increase their prices in other countries.
"There will still be plenty of money for research and development purposes, but it's just the United States alone will not be bearing that cost," a White House official said on a call with reporters on Monday.
Essentially, in keeping with the president's view that the U.S. often carries the weight of other countries and gets the short end of the stick, this drug pricing policy will attempt to redistribute some of the U.S.'s prescription drug costs onto other countries.

The U.S. accounts for less than 5% of the world's population but roughly three-quarters of global pharmaceutical profits, officials said.
Domestically, the White House will direct Health and Human Services Secretary Robert F. Kennedy Jr. to "set clear targets for price reductions across all markets in the United States," not just in government-funded Medicare programs, within the next 30 days.
"If adequate progress is not made towards these price reduction targets, the secretary of Health and Human Services will impose most favored nation pricing via rulemaking," a White House official said.
The administration was sparse on details about which drugs will be prioritized, but said it will look at the costliest medications and likely include weight loss drugs.
-ABC News' Youri Benadjaoud and Cheyenne Haslett